SCHEMBL4471523

SCHEMBL4471523

CC(C)Cn1c(=O)n(C)c(=O)c2c1ncn2CCN1CCN(c2ncccn2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.57
PDE1B Q01064 1/20 0.57
PDE1C Q14123 1/20 0.57
HTR7 P34969 1/20 0.48
HTR6 P50406 1/20 0.48
PDE4A P27815 5/20 0.47
PDE4B Q07343 5/20 0.47
PDE4C Q08493 5/20 0.47
PDE4D Q08499 5/20 0.47
ADORA2A P29274 4/20 0.47
ADORA2B P29275 3/20 0.47
HTR1A P08908 3/20 0.45
HTR2A P28223 3/20 0.45
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480786 0.88 PDE1A (0.58) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4468785 0.87 HTR7 (0.64) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4475749 0.86 HTR7 (0.62) HTR7HTR6ADORA2BHTR1AHTR2A
SCHEMBL4462967 0.84 PDE1A (0.61) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4476464 0.83 PDE1A (0.57) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4460765 0.83 PDE1A (0.77) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4480724 0.83 MAPK1 (0.57) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4461504 0.82 L3MBTL1 (0.58) PDE1APDE1BPDE1CHTR7HTR1A
SCHEMBL4473899 0.81 PDE1A (0.54) PDE1APDE1BPDE1CHTR7HTR6
SCHEMBL4462921 0.80 PDE1A (0.60) PDE1APDE1BPDE1CHTR7HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550468-B2 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2009-06-23 US disclosed
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase CHEN ING-JUN 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209242-A1 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase PDE3A, PDE5A, PDE3B PDE1A 22/4885PDE1B 24/4885PDE1C 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.